30,32 Notably, CDK8/19 inhibitors have reached clinical trials for solid tumors and leukemias (clinicaltrials.govNCT03065010, NCT04021368, NCT05052255, NCT05300438), however no prior study has assessed their utility in ovarian cancer models. Here, CDK8 is linked to ovarian carcinoma.